For years, the stock of Corvas International Inc. has languished, even though the company has had interesting cardiovascular programs in anticoagulants to treat deep vein thrombosis and stroke. But the company has attracted institutional investor interest this year, capping it off this month by raising $115 million in a public offering (see BioCentury, Nov. 6).

The key to finally catching investors' interest has been a combination of events leading to critical mass, including a successful $15 million private offering based on a refocused R&D strategy and validation of the company's pharmaceutical partnerships and clinical programs.